Immunotherapy Prolongs Survival in Patients with Rare Skin Cancer
A groundbreaking clinical study led by researchers at UCLA has revealed that pembrolizumab—a potent immunotherapy drug targeting the PD-1 receptor—can induce remarkable and sustained tumor...